Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington & Burling Advises Medarex on Biotechnology Acquisition

October 14, 2005

LONDON, UK, October 14, 2005 -  Covington & Burling assisted Medarex, the biopharmaceutical company focused on human antibody-based therapeutics to treat life-threatening and debilitating diseases, on the acquisition by its subsidiary Celldex Therapeutics Limited of privately held biotechnology company, Lorantis Ltd.

Celldex will acquire Lorantis for 6.8 million shares of Celldex common stock.   Lorantis' assets include cash of approximately $30 million and a pre-clinical program based upon Lorantis' discovery of a fundamental immune mechanism that can selectively modulate immune response known as the Notch signalling pathway. 

The Covington team was led by corporate lawyers Simon Goodworth and Simon Gamblin in London, and the Medarex team by Beth Behrend, Deputy General Counsel and Brad Middlekauff, General Counsel.  Dwight A. Kinsey of Satterlee Stephens Burke & Burke advised on U.S .law aspects of the transaction.

Share this article: